

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 6185)

INSIDE INFORMATION

**THE PROGRESS OF PROPOSED ISSUE OF A SHARES
FINANCIAL INFORMATION IN RELATION TO A SHARE PROSPECTUS**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiary, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the Company's announcements dated October 14, 2019, January 22, 2020, February 3, 2020, March 19, 2020 and April 14, 2020, circular dated October 14, 2019 and supplemental circular dated November 14, 2019 containing, among other things, related matters of the proposed initial public issue of A Shares (the “**Proposed Issue of A Shares**”) and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange.

The Company has submitted a prospectus of the A Share offering (Submission Proof) (the “**Submission Proof Prospectus**”), the Response to the Opinion Implementation Letter of the Review Center for the Initial Public Offering and Listing on the Science and Technology Innovation Board of CanSino Biologics Inc. and related materials in connection with the Proposed Issue of A Shares on April 20, 2020, which have been published on the website of the Review and Approval of the Issuance and Listing of Stocks on the Science and Technology Innovation Board of the Shanghai Stock Exchange (上交所科創板股票發行上市審核網站) at kcb.sse.com.cn.

The Submission Proof Prospectus contains, among other things, certain key financial information of the Group for the three months ended March 31, 2020 (the “**Key Financial Information**”). The Key Financial Information is prepared in accordance with the Chinese Accounting Standards for Business Enterprises, the details of which are as follows:

	Three months ended March 31,		Changes	
	2020	2019	RMB'000	%
	RMB'000	RMB'000		
	(Unaudited)	(Unaudited)		
Operating income	4,030	572	3,458	605.10%
Net profit	(23,103)	(45,248)	22,145	-48.94%
Profit attributable to owners of the Company	(23,103)	(45,248)	22,145	-48.94%
Profit attributable to owners of the Company after deducting non-recurring gains and losses	(35,344)	(47,677)	12,333	-25.87%

The above English version of the summary of the Key Financial Information is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

As the Proposed Issue of A Shares is subject to certain conditions precedent, it may or may not be completed. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the H shares of the Company. Further announcement(s) regarding the details and developments of the Proposed Issue of A Shares will be made by the Company as and when appropriate. This announcement appears for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 21, 2020

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.